{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:40:21Z","timestamp":1791204021841,"version":"4.2.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Aim of the review<\/jats:title>\n                    <jats:p>To assess the risk of hypovolemia for sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 October 2022, Data for study characteristics and outcomes of interest were extracted from each eligible study. Risk ratios (RRs) with a 95% confidence interval (CI) for hypovolemia were calculated using a random-effect model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 57 studies (\n                      <jats:italic>n<\/jats:italic>\n                      = 68,622) were included in our meta-analysis, with a result of 1,972 hypovolemia incidents (1,142 in the SGLT2 inhibitors group and 830 in the control group). The pooled RR was 1.12 (95% CI: 1.02\u20131.22). It is evident that receiving SGLT2 inhibitors increased the risk of hypovolemia. When stratified by category of SGLT2 inhibitors the result was consistent; when the subgroup was analyzed by age, the pooled RR was 1.07 (95% CI: 0.94\u20131.23) in patients aged \u226565 years and 1.14 (95% CI: 1.02\u20131.28) in those aged &amp;lt;65 years. When comparing the baseline estimated glomerular filtration rate (eGFR) of less than or equal to 60 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      with a baseline eGFR greater than 60 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , the pooled RR was 1.21, (95% CI: 1.00\u20131.46) and 1.08, (95%CI: 0.98\u20131.20), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our meta-analysis has demonstrated that SGLT2 inhibitors increased the risk of hypovolemia in patients with Type 2 Diabetes Mellitus (T2DM). It is necessary to pay attention to the risk of hypovolemia associated with SGLT2 inhibitors, especially in older individuals and those with moderate renal impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      ], identifier [CRD42020156254].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2022.973129","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:11:10Z","timestamp":1668384670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Risk of hypovolemia associated with sodium\u2013glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Xi","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiling","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00125-019-4909-y","article-title":"Type 2 diabetes: a multifaceted disease.","volume":"62","author":"Pearson","year":"2019","journal-title":"Diabetologia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1001\/jama.2017.7596","article-title":"Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013.","volume":"317","author":"Wang","year":"2017","journal-title":"JAMA."},{"key":"B3","year":"2016","journal-title":"Global Report on Diabetes."},{"key":"B4","doi-asserted-by":"publisher","first-page":"Itc1","DOI":"10.7326\/AITC201503030","article-title":"In the clinic. type 2 diabetes.","volume":"162","author":"Vijan","year":"2015","journal-title":"Ann Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology.","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obesity Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care."},{"key":"B12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range.","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obesity Metab."},{"key":"B13","first-page":"S27","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial.","volume":"138","author":"Wilding","year":"2013","journal-title":"Deutsche Medizin Wochensch."},{"key":"B14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.","volume":"56","author":"Lavalle-Gonzalez","year":"2013","journal-title":"Diabetologia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care."},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obesity Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obesity Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obesity Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care."},{"key":"B24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Adv Therapy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1185\/03007995.2014.901943","article-title":"Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1185\/03007995.2014.909390","article-title":"Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","article-title":"Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.","volume":"15","author":"Inagaki","year":"2014","journal-title":"Expert Opin Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1475-2840-13-65","article-title":"Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.","volume":"13","author":"Kaku","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obesity Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/dom.12385","article-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.","volume":"17","author":"Ji","year":"2015","journal-title":"Diabetes Obesity Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obesity Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dme.12814","article-title":"Empagliflozin as add-on to metformin in people with Type 2 diabetes.","volume":"32","author":"Merker","year":"2015","journal-title":"Diabetic Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.12469","article-title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.","volume":"17","author":"Ross","year":"2015","journal-title":"Diabetes Obesity Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jdi.12316","article-title":"Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.","volume":"6","author":"Seino","year":"2015","journal-title":"J Diabetes Investig."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dc14-0666","article-title":"Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-Week randomized, double-blind clinical trial.","volume":"38","author":"Matthaei","year":"2015","journal-title":"Diabetes Care."},{"key":"B42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care."},{"key":"B43","first-page":"382","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.","volume":"37","author":"Bailey","year":"2016","journal-title":"Therap Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/dom.12745","article-title":"Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.","volume":"18","author":"Ishihara","year":"2016","journal-title":"Diabetes Obesity Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obesity Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/dom.12649","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes Obesity Metab."},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obesity Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/03007995.2018.1441816","article-title":"Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.","volume":"34","author":"Seino","year":"2018","journal-title":"Curr Med Res Opin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.13213","article-title":"Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP\/INS).","volume":"20","author":"Terauchi","year":"2018","journal-title":"Diabetes Obesity Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1753-0407.12634","article-title":"Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial.","volume":"10","author":"Yang","year":"2018","journal-title":"J Diabetes."},{"key":"B53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1053\/j.ajkd.2019.03.417","article-title":"Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a\/3b CKD.","volume":"74","author":"Allegretti","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation."},{"key":"B56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/jdi.12985","article-title":"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial.","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig."},{"key":"B58","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"B60","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF).","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation."},{"key":"B61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 Diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cjca.2019.11.036","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis.","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Can J Cardiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1161\/CIRCULATIONAHA.119.040909","article-title":"Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events.","volume":"140","author":"Packer","year":"2019","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure.","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s13300-019-0674-7","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in East Asians with type 2 diabetes: a systematic review and meta-analysis.","volume":"10","author":"Yang","year":"2019","journal-title":"Diabetes Therapy."},{"key":"B68","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/00325481.2016.1153941","article-title":"Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.","volume":"128","author":"Johnsson","year":"2016","journal-title":"Postgrad Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside.","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care."},{"key":"B70","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology.","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.973129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:11:16Z","timestamp":1668384676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.973129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":70,"alternative-id":["10.3389\/fcvm.2022.973129"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.973129","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"article-number":"973129"}}